Circulation-Heart Failure

Papers
(The H4-Index of Circulation-Heart Failure is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Two-Year Follow Up of the LATERAL Clinical Trial149
Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure132
Unraveling Comorbidities Contribution to Cardiac Diastolic Dysfunction and Heart Failure83
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program64
Unraveling the Role of Myocardial Inflammation in ATTR-CM: A Targetable Mechanism?61
Systemic Circulation in Advanced Heart Failure and Cardiogenic Shock: State-of-the-Art Review60
Letter by Jha Regarding Article, “Pathophysiologic Vasodilation in Cardiogenic Shock and Its Impact on Mortality”59
Plasma SVEP1 Levels Predict Cardiovascular Events in Hypertrophic Cardiomyopathy Beyond Conventional Clinical Risk Models Including NT-proBNP49
Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis46
Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction42
Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group41
Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes40
Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System40
It’s Not You, It’s Me: Uncovering Heart-Kidney Relationship Failures40
Edge-to-Edge Transcatheter Mitral Valve Repair Versus Optimal Medical Treatment in Nonresponders to Cardiac Resynchronization Therapy: The MITRA-CRT Trial38
Longitudinal Invasive Hemodynamic Assessment in Patients With Acute Decompensated Heart Failure–Related Cardiogenic Shock: A Single-Center Experience38
SUSTAINing the Care of Patients With Advanced Heart Failure by Supporting Family Caregivers37
Temporary Mechanical Circulatory Support Coordinator: Conception and Implementation of a Novel Role37
Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial36
Challenges for Patients Dying of Heart Failure and Cancer35
Diurnal Variations in Natriuretic Peptide Levels: Clinical Implications for the Diagnosis of Acute Heart Failure35
Why We Should Care About Who Cares for Patients With Heart Failure With Preserved Ejection Fraction35
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNA -Related Dilated Cardiomyopathy35
Diastolic Dysfunction Is Unmasked on Exercise in Patients With Asymptomatic, Severe Aortic Stenosis: An Invasive Hemodynamic Study34
Finerenone Improves Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF33
High-Intensity Care Versus GDMT Titration: Which Rapidly Improves Health Status in Patients With Heart Failure?32
Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction32
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials32
Trending Cardiac Biomarkers During Pregnancy in Women With Cardiovascular Disease31
GDMT Optimization, But Make It Patient-Centered: Understanding Patient Needs During Heart Failure Medication Discussions31
Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial31
Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial31
0.03801703453064